Pharmaceuticals 2013, 6(4), 557-578; doi:10.3390/ph6040557

Biologics in Dermatology

1 London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK 2 Whipps Cross University Hospital and the Royal London Hospital, Whitechapel, E1 1BB, London, UK
* Author to whom correspondence should be addressed.
Received: 31 January 2013; in revised form: 26 February 2013 / Accepted: 7 April 2013 / Published: 17 April 2013
(This article belongs to the Special Issue Biologics)
PDF Full-text Download PDF Full-Text [485 KB, uploaded 17 April 2013 15:02 CEST]
Abstract: Skin and subcutaneous diseases affect millions of people worldwide, causing significant morbidity. Biologics are becoming increasingly useful for the treatment of many skin diseases, particularly as alternatives for patients who have failed to tolerate or respond to conventional systemic therapies. Biological therapies provide a targeted approach to treatment through interaction with specific components of the underlying immune and inflammatory disease processes. This review article examines the increasing evidence base for biologics in dermatology, including well-established treatments and novel agents.
Keywords: biologics; biological response modifiers; immunopathogenesis; dermatology; skin disease

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Chandler, D.; Bewley, A. Biologics in Dermatology. Pharmaceuticals 2013, 6, 557-578.

AMA Style

Chandler D, Bewley A. Biologics in Dermatology. Pharmaceuticals. 2013; 6(4):557-578.

Chicago/Turabian Style

Chandler, David; Bewley, Anthony. 2013. "Biologics in Dermatology." Pharmaceuticals 6, no. 4: 557-578.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert